What Is Medullary Nephrocalcinosis?

Medullary nephrocalcinosis is a condition in which calcium salts build up inside the inner portion of the kidney, specifically the medulla, which is the tissue that funnels urine toward the collecting system. It accounts for roughly 97% of all nephrocalcinosis cases, making it far more common than the cortical form, where calcium deposits instead settle in the outer kidney tissue.¹ The condition is not the same as a kidney stone, though the two are related and sometimes coexist. Understanding the distinction matters because medullary nephrocalcinosis carries its own risks for long-term kidney health.

How Medullary Nephrocalcinosis Differs From Kidney Stones

People often confuse nephrocalcinosis with kidney stones, and the two can look similar on imaging. But they form in different places and behave differently. A kidney stone sits in the open spaces of the urinary tract, like the renal pelvis or a calyx, where urine collects. Medullary nephrocalcinosis, by contrast, involves calcium deposits embedded within the kidney tissue itself, typically in the renal pyramids and papillae. You can think of it as calcification baked into the kidney’s architecture rather than a loose rock rattling around in the plumbing.

This distinction is more than academic. Research on primary hyperoxaluria found that nephrocalcinosis and kidney stones appear to be pathophysiologically distinct entities, and the presence of nephrocalcinosis specifically carries an increased risk for end-stage kidney disease.² In other words, while kidney stones are painful and disruptive, the calcium infiltrating the medullary tissue itself poses a more insidious threat to how well the kidney works over time.

Where the Calcium Deposits Form

The renal medulla is the inner region of the kidney, made up of cone-shaped structures called pyramids. These pyramids contain the loops of Henle and collecting ducts, the tubular plumbing that concentrates urine. In medullary nephrocalcinosis, calcium crystals first appear in the basement membrane surrounding the thin loops of Henle, then spread outward through the surrounding tissue toward the inner lining of the urinary tract.³ Within the basement membrane, these mineral deposits are tiny layered particles where zones of crystal alternate with organic material. As they spread into the surrounding interstitium, the particles fuse along collagen fibers, creating what researchers describe as a patchwork of crystal islands in an organic sea.

When the lining tissue loses its integrity and these deposits become exposed to urine, proteins and additional crystals can layer onto the surface. This is one pathway through which medullary calcification can eventually seed actual kidney stones, a process sometimes called the Randall plaque progression. It helps explain why people with medullary nephrocalcinosis often develop stones on top of the underlying tissue calcification.

Common Causes

Medullary nephrocalcinosis is not a disease in itself but rather a consequence of some other underlying problem. The list of causes is long, spanning metabolic disorders, genetic conditions, structural kidney abnormalities, and medication side effects. A few categories stand out as the most frequent culprits.

Elevated Calcium and Parathyroid Disorders

The single most common cause in adults is primary hyperparathyroidism, a condition where one or more parathyroid glands produce too much parathyroid hormone. This drives blood calcium levels up, and the kidneys filter out the excess, flooding the tubules with calcium that can crystallize in the medullary tissue.⁴ Chronic high blood calcium from other causes, including certain cancers and excessive vitamin D intake, can produce the same result. In animal studies, sustained elevation of blood calcium led to a measurable drop in the kidney’s ability to concentrate urine, even before the filtering capacity declined.⁵ That concentration defect is one of the earliest functional signs of medullary damage.

Renal Tubular Acidosis

Distal renal tubular acidosis (often called type 1 RTA) is another classic cause. In this condition, the kidney’s distal tubules cannot properly acidify urine. The resulting alkaline urine environment makes it much easier for calcium phosphate to precipitate out and deposit in the medulla. Even an incomplete form of the disorder, where routine blood tests look normal, can produce medullary nephrocalcinosis. One well-documented case involved a patient with bilateral medullary calcification whose standard acid-base tests were unremarkable; only a specialized acidification challenge test revealed the tubular defect.⁶ That case is a useful reminder that the incomplete form can fly under the radar for years while quietly calcifying the kidneys.

Medullary Sponge Kidney

Medullary sponge kidney (MSK) is a congenital malformation in which the collecting ducts near the tips of the renal pyramids become abnormally dilated, forming tiny cysts.⁷ These stagnant pools of urine are ideal breeding grounds for crystal formation. MSK generally shows up as nephrocalcinosis and recurrent kidney stones, often accompanied by acidification and concentration defects in the affected tubules.⁸ On ultrasound, the medullary regions of both kidneys typically appear brightly echogenic, a hallmark pattern that radiologists recognize as the combination of MSK and medullary nephrocalcinosis.⁹

Rare Genetic Tubulopathies

Several inherited conditions affecting the kidney tubules lead to medullary nephrocalcinosis, usually presenting in childhood. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is caused by mutations in the CLDN16 or CLDN19 genes, which encode proteins critical for calcium and magnesium handling in the kidney.¹⁰ Dent disease, an X-linked condition caused by mutations in the CLCN5 or OCRL1 genes, produces a distinctive package of symptoms including excessive urinary calcium loss, protein in the urine, nephrocalcinosis, and progressive kidney failure. Only about 250 families worldwide have been identified with these mutations.¹¹ These conditions are rare individually, but collectively they represent an important group to consider when medullary nephrocalcinosis appears in a young patient without an obvious metabolic explanation.

Drug-Induced Medullary Nephrocalcinosis in Premature Infants

One of the most well-studied settings for medullary nephrocalcinosis is the neonatal intensive care unit. Premature infants with chronic lung disease are often treated with furosemide, a powerful loop diuretic. This drug increases calcium excretion in the urine, and in tiny, immature kidneys, that extra calcium load can quickly calcify the medulla.¹²

The risk is dose-dependent. A critical review of observational data found that cumulative furosemide doses were substantially higher in infants who developed nephrocalcinosis compared to those who did not, with risk climbing particularly when cumulative doses exceeded about 10 mg/kg. Treatment courses lasting longer than two to three weeks were especially problematic.¹³ The reassuring news is that roughly two-thirds of cases resolved on their own once the drug was stopped, though persistent calcification was linked to longer exposure, higher doses, and signs of tubular kidney damage.

This is not just a historical curiosity. Furosemide remains widely used in NICUs, and screening ultrasounds during or shortly after treatment are standard practice in many centers. It is one of the few scenarios where medullary nephrocalcinosis is iatrogenic, meaning directly caused by medical treatment, and therefore largely preventable through careful dosing.

The Role of Vitamin D and Granulomatous Disease

Excessive vitamin D, whether from overzealous supplementation or an underlying disease process, is another route to medullary nephrocalcinosis. High vitamin D levels drive intestinal calcium absorption up, raising blood and urinary calcium. Granulomatous diseases like sarcoidosis add a dangerous twist: the immune cells forming granulomas contain an enzyme that converts inactive vitamin D into its active form outside the kidney’s normal regulatory control. In one reported case, a patient with sarcoidosis developed acute kidney failure, kidney stones, and dangerously high calcium after uncontrolled vitamin D3 supplementation, because the granulomas were turbocharging activation of the supplement.¹⁴

For anyone with a known granulomatous condition, vitamin D supplementation needs to be handled with extra caution and regular monitoring of blood calcium levels. The general public trend toward high-dose vitamin D supplements without medical guidance also creates risk, though usually at doses well above what most people take.

How It Is Detected

Medullary nephrocalcinosis is often discovered incidentally on imaging done for other reasons, because early stages produce no symptoms at all. Ultrasound is the first-line detection tool, and it picks up the calcification as bright, echogenic pyramids in the medullary region. A classification scheme developed in the 1980s describes four ultrasound patterns: a bright band around the periphery of each pyramid, increased brightness throughout the pyramid, globally echogenic pyramids, and focal bright spots at the tips of the pyramids near the fornices.¹⁵ That last pattern corresponds to the Randall plaque progression and is associated with stone formation.

CT scans are more sensitive than ultrasound and can catch milder calcification that ultrasound misses. On CT, the renal pyramids show increased density compared to the surrounding cortex. CT is also better at distinguishing medullary nephrocalcinosis from the much rarer cortical form, where calcifications sit in the outer kidney. The two forms occasionally occur together in conditions like oxalosis and chronic kidney infections.¹

Once imaging confirms medullary nephrocalcinosis, the real diagnostic work begins: figuring out why it happened. This typically involves blood tests for calcium, phosphate, parathyroid hormone, and vitamin D, along with a 24-hour urine collection measuring calcium, oxalate, citrate, and pH. Genetic testing may follow if the pattern suggests a hereditary cause, especially in children.

Symptoms and When People Notice Something Is Wrong

Mild medullary nephrocalcinosis can be entirely silent. Many people learn about it only when an abdominal ultrasound or CT done for unrelated reasons lights up the renal pyramids. As the condition progresses, symptoms tend to emerge from two directions: the kidney stones that often form alongside the tissue calcification, and the gradual decline in kidney function.

Stone-related symptoms include the classic flank pain, blood in the urine, and recurrent urinary tract infections. The functional symptoms are subtler. Because the medulla is where the kidney concentrates urine, early damage there can cause an inability to concentrate urine properly. You might notice that you are producing large volumes of dilute urine and feeling unusually thirsty, symptoms that overlap with many other conditions and are easy to brush off.

In children, the presentation can be different. Growth retardation, poor bone mineralization, and problems with intestinal absorption may be among the first recognized signs, particularly when the nephrocalcinosis is driven by a genetic tubulopathy.¹⁶ Pediatricians evaluating a child who is failing to thrive should consider medullary nephrocalcinosis as part of the workup, especially if there is a family history of kidney problems.

Treatment Focuses on the Underlying Cause

There is no way to dissolve calcium deposits already embedded in the kidney tissue. Treatment is entirely about identifying and correcting the condition that caused the calcification, preventing further deposition, and managing complications like kidney stones.

For hyperparathyroidism, surgical removal of the overactive gland typically halts the process. For distal renal tubular acidosis, alkali therapy (usually potassium citrate) corrects the acid-base imbalance and reduces urinary calcium while raising urinary citrate, which naturally inhibits crystal formation. The same medication has proven effective for medullary sponge kidney: a long-term study found that potassium citrate treatment dramatically reduced the rate of new stone events from about 0.58 to 0.10 stones per year per patient, alongside significant increases in urinary citrate and decreases in urinary calcium.¹⁷

For drug-induced cases in premature infants, the primary intervention is discontinuing or reducing the offending medication when clinically possible. As noted earlier, the majority of neonatal cases resolve after furosemide is stopped.

High fluid intake is widely considered the cornerstone of prevention for all calcium-related kidney problems, and this holds for medullary nephrocalcinosis. Reducing dietary salt and animal protein has also been explored, though the evidence on those dietary changes is less definitive.¹⁸ Drinking enough water to produce at least two liters of urine per day is a practical target most doctors recommend.

Long-Term Outlook and Kidney Function

The prognosis of medullary nephrocalcinosis depends almost entirely on what is causing it and how early it is caught. Some causes, like furosemide exposure in a premature infant, can resolve completely. Others, like certain genetic tubulopathies, march steadily toward chronic kidney disease regardless of treatment. In general, nephrocalcinosis can progress to chronic kidney failure, and in severe cases, dialysis or transplantation may eventually be needed.¹⁹

Regular monitoring is essential once the diagnosis is made. This typically means periodic imaging to track whether the calcification is stable, growing, or resolving, combined with blood and urine tests to assess kidney function and the metabolic parameters driving the calcification. The goal of surveillance is to catch any worsening early enough to adjust treatment before irreversible damage accumulates.

Why the Medulla Is So Vulnerable

It is worth asking why calcium deposits so preferentially target the medulla rather than the cortex. The answer lies in the medulla’s unique physiology. The inner medulla is the most concentrated environment in the body: the countercurrent mechanism that allows the kidney to produce concentrated urine creates extremely high solute concentrations deep in the medullary pyramids. Calcium, phosphate, and oxalate can reach supersaturation levels in this environment that would never occur in the cortex or anywhere else in the body. Additionally, the medullary blood supply is relatively sparse compared to the cortex, meaning the tissue is already operating in a low-oxygen, high-stress environment. Combine supersaturated solutes with limited blood flow and the physical architecture of loops and ducts where flow slows down, and you have the perfect recipe for crystal nucleation and growth.

Cortical nephrocalcinosis, by comparison, usually requires a much more dramatic insult, such as widespread cortical necrosis from shock or severe infection, to trigger calcium deposition in that well-perfused, less concentrated outer tissue. This explains the roughly 20-to-1 ratio favoring medullary over cortical involvement.

Genetic Testing and the Expanding Landscape

The number of recognized genetic causes of medullary nephrocalcinosis has expanded considerably in recent years. Beyond the FHHNC and Dent disease examples mentioned earlier, the list now includes Bartter syndrome, familial hypomagnesemia, certain forms of hereditary hypercalciuria, and other rare tubulopathies.²⁰ For a patient with unexplained medullary nephrocalcinosis, especially one who is young or has a family history, genetic testing panels targeting renal tubular genes can sometimes provide a definitive diagnosis where traditional metabolic workups come up empty.

Getting a genetic diagnosis does more than satisfy curiosity. It can guide prognosis, since some mutations carry a high risk of progressive kidney failure while others are relatively benign. It can also inform family screening, because many of these conditions are autosomal recessive, meaning both parents are carriers and other siblings may be affected but undiagnosed. For conditions like FHHNC with CLDN19 mutations, there are also extrarenal complications such as eye abnormalities that clinicians need to watch for once the specific gene is identified.¹⁰